Ubrogepant (CAS 1374248-77-7): A Comprehensive Product Introduction
Ubrogepant, with the CAS number 1374248-77-7, is a significant pharmaceutical compound that has been gaining attention in the medical field. It belongs to a class of drugs known as calcitonin gene-related peptide (CGRP) receptor antagonists. This compound has shown great potential in the treatment of various medical conditions, especially migraines. In this article, we will explore the properties, uses, applications in different fields, and the preparation methods of Ubrogepant in detail.
Properties of Ubrogepant
Ubrogepant is a white to off – white powder. Its chemical formula is C₂₃H₂₃F₃N₆O₂. It has a molecular weight of approximately 472.46 g/mol. The compound is sparingly soluble in water, which is an important physical property that affects its formulation and delivery in pharmaceutical products. It has a relatively stable chemical structure under normal storage conditions, but like many pharmaceutical compounds, it should be stored in a cool, dry place away from direct sunlight and moisture to maintain its stability.
The solubility of Ubrogepant in different solvents can vary significantly. For example, it may have better solubility in some organic solvents such as ethanol or dimethyl sulfoxide (DMSO). This property is crucial for its use in laboratory research, where it may need to be dissolved in specific solvents for various assays and experiments. In addition, the melting point and boiling point of Ubrogepant are important parameters that can be used to identify and purify the compound during its synthesis and production process.
Uses of Ubrogepant
The primary use of Ubrogepant is in the treatment of migraines. Migraines are a common and often debilitating neurological disorder characterized by severe headaches, often accompanied by nausea, vomiting, and sensitivity to light and sound. Ubrogepant works by blocking the CGRP receptor. CGRP is a neuropeptide that is believed to play a key role in the pathophysiology of migraines. By inhibiting the binding of CGRP to its receptor, Ubrogepant can reduce the pain and other symptoms associated with migraines.
Clinical trials have shown that Ubrogepant can provide rapid relief from migraine pain. It is available as an oral tablet, which makes it a convenient option for patients. Unlike some other migraine medications, Ubrogepant does not have the vasoconstrictive effects that are associated with traditional triptan medications. This makes it a potentially safer option for patients with certain cardiovascular conditions, as vasoconstriction can pose risks such as increased blood pressure and reduced blood flow to the heart and other organs.
Another potential use of Ubrogepant is in the prevention of migraines. While its primary indication is for acute treatment, some studies are exploring its effectiveness in reducing the frequency and severity of migraines when used on a regular basis. However, more research is needed in this area to establish its efficacy and safety for migraine prevention.
Applications in Different Fields
Medical Field: As mentioned earlier, the main application of Ubrogepant in the medical field is in the treatment of migraines. It offers a new treatment option for patients who do not respond well to traditional migraine medications or who have contraindications to these medications. In addition to its use in adult patients, there is also ongoing research on the safety and efficacy of Ubrogepant in pediatric patients with migraines.
Pharmaceutical Industry: Ubrogepant is an important product for pharmaceutical companies. The development and production of Ubrogepant require strict quality control and compliance with regulatory standards. Pharmaceutical companies are involved in the synthesis, formulation, and packaging of Ubrogepant products. They also conduct clinical trials to ensure the safety and efficacy of the drug before it can be approved for market use. In addition, the pharmaceutical industry is constantly researching and developing new formulations of Ubrogepant to improve its bioavailability and patient compliance.
Research Field: Ubrogepant is also a valuable tool in scientific research. It can be used in studies to understand the role of CGRP in the nervous system and its relationship with migraines and other neurological disorders. Researchers can use Ubrogepant to investigate the mechanism of action of CGRP receptor antagonists and to develop new drugs with improved efficacy and safety profiles. In addition, Ubrogepant can be used in pre – clinical studies to evaluate the potential of new drug candidates for migraine treatment.
Preparation Methods of Ubrogepant
The preparation of Ubrogepant involves a series of chemical reactions. One common synthetic route starts with the synthesis of key intermediates. These intermediates are then combined and further modified through a series of steps to form the final Ubrogepant product.
The first step usually involves the synthesis of a specific heterocyclic compound, which serves as the core structure of Ubrogepant. This heterocyclic compound is often synthesized through a multi – step reaction sequence, including cyclization reactions and functional group transformations. After the synthesis of the core heterocyclic compound, various substituents are introduced to the molecule to obtain the desired chemical structure of Ubrogepant.
The synthesis process requires the use of various reagents and catalysts. For example, some reactions may require the use of strong acids or bases, while others may need transition metal catalysts. The reaction conditions, such as temperature, pressure, and reaction time, also need to be carefully controlled to ensure high yields and purity of the final product. After the synthesis is completed, the Ubrogepant product is usually purified through techniques such as recrystallization, chromatography, or distillation to remove impurities and obtain a high – quality product.
Send InquiryReferences
- Author 1. “Title of Article 1”. Journal Name 1, Volume, Issue, Page numbers (Year).
- Author 2. “Title of Article 2”. Journal Name 2, Volume, Issue, Page numbers (Year).